文献速递胸部肿瘤放疗

螺旋断层放疗中度和常规分割放疗联合同期化疗治疗不可切除Ⅲ期非小细胞肺癌的疗效与毒性:多中心随机Ⅲ期试验

Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-04-15

这项多中心随机非盲Ⅲ期试验将146例不可切除Ⅲ期非小细胞肺癌患者按1:1分为螺旋断层放疗中度大分割组(60 Gy/20次)和常规分割组(60 Gy/30次),均接受2周期同期铂类化疗加2周期巩固治疗。中度大分割组3年总生存率58.4%高于常规分割组38.4%(P=.02),中位总生存41个月对30个月(HR 0.61,95%CI 0.40-0.94,P=.02),两组≥2级治疗相关不良事件发生率无显著差异。

要点

  • 中度大分割组3年总生存率58.4%高于常规分割组38.4%(P=.02)。
  • 中度大分割组中位总生存41个月长于常规分割组30个月(HR 0.61,95%CI 0.40-0.94)。
  • 两组≥2级治疗相关不良事件发生率无显著差异。

核心结论

  • 使用螺旋断层放疗的中度大分割放疗可能改善不可切除Ⅲ期非小细胞肺癌患者的总生存,同时维持毒性发生率。

研究设计与样本

  • 多中心、随机、非盲Ⅲ期临床试验,2018年7月27日至2021年11月1日共入组146例不可切除Ⅲ期非小细胞肺癌患者,按1:1随机分为中度大分割组(60 Gy/20次)和常规分割组(60 Gy/30次)。
  • 所有患者接受2周期同期铂类化疗加2周期巩固治疗,主要终点为意向治疗人群的3年总生存率,次要终点为无进展生存和治疗相关不良事件。

主要发现

  • 中位随访46个月,中度大分割组和常规分割组3年总生存率分别为58.4%和38.4%(P=.02)。
  • 自随机分组起中位总生存中度大分割组为41个月,常规分割组为30个月(HR 0.61,95%CI 0.40-0.94,P=.02)。
  • 两组≥2级治疗相关不良事件发生率无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The standard treatment schedule for unresectable stage III non-small cell lung cancer (NSCLC) is chemotherapy with concurrent radiation therapy (60 Gy delivered in 30 fractions), although moderately hypofractionated radiation therapy (Hypo-RT) has also been considered as an alternative strategy. This study aimed to compare the efficacy and toxicity of moderately Hypo-RT with helical TomoTherapy versus conventionally fractionated radiation therapy (Con-RT) in patients with unresectable stage III NSCLC receiving concurrent chemotherapy. METHODS AND MATERIALS: In this randomized, multicenter, nonblinded phase 3 clinical trial, eligible patients were randomised at a 1:1 ratio to either the Hypo-RT group (60 Gy in 20 fractions) or Con-RT group (60 Gy in 30 fractions). All patients received 2 cycles of concurrent platinum-based chemotherapy plus 2 cycles of consolidation therapy. The primary endpoint was 3-year overall survival (OS) in the intention-to-treat population. The secondary endpoints were progression-free survival and treatment-related adverse events. RESULTS: A total of 146 patients were enrolled from July 27, 2018, to November 1, 2021. The median follow-up was 46 months. The 3-year OS rates in the Hypo-RT and Con-RT groups were 58.4% and 38.4%, respectively (P = .02). The median OS from randomisation was 41 months in the Hypo-RT group and 30 months in the Con-RT group (hazard ratio, 0.61; 95% confidence interval, 0.40-0.94; P = .02). There was no significant difference in the rates of grade ≥2 treatment-related adverse events between the 2 groups. CONCLUSIONS: Moderately Hypo-RT using helical TomoTherapy may improve OS in patients with unresectable stage III NSCLC, while maintaining toxicity rates.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zhang Q, Fan S, Xu X, et al. Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 38631536. doi:10.1016/j.ijrobp.2024.03.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。